Table 4 Modulating effects of laquinimod on activation status of slanDC
From: Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
| Placebo | Laquinimod | |||||
|---|---|---|---|---|---|---|
| Parameter | n | Mean | Std Err | n | Mean | Std Err |
| SlanDC CD83-culture LPS (%) difference from baseline | 13 | −2.3 | 5.6 | 31 | −18.8 | 4.2 |
| SlanDC CD83-culture R848 (%) difference from baseline | 13 | −5.5 | 6.4 | 31 | −16.5 | 3.2 |
| SlanDC TNF-culture LPS (%) difference from baseline | 15 | −3.0 | 3.2 | 37 | −9.4 | 2.5 |
| SlanDC TNF-culture R848 (%) difference from baseline | 15 | −2.3 | 3.1 | 37 | −8.9 | 2.3 |